The present invention relates to a method for preventing stem cell disruption and aggregation. The present invention also relates to a stem cell composition for intravascular administration, in which stem cells are suspended in a solution containing aspirin. The present invention also relates to a composition for preventing stem cell disruption or aggregation, in which stem cells are suspending in a solution containing aspirin. According to the present invention, cell disruption and aggregation can be prevented during transport or storage, thus enabling the administered stem cells to stably reach target tissue and exhibit the activity thereof in a more efficient manner, thereby remarkably increasing the effects of cell therapy using stem cells.La présente invention concerne un procédé pour la prévention de la dégradation et de lagrégation de cellules souches. La présente invention concerne également une composition de cellules souches pour ladministration intravasculaire, dans laquelle des cellules souches sont mises en suspension dans une solution contenant de laspirine. La présente invention concerne également une composition pour la prévention de la dégradation ou de lagrégation de cellules souches, dans laquelle des cellules souches sont mises en suspension dans une solution contenant de laspirine. Selon la présente invention, la dégradation et lagrégation cellulaire peuvent être empêchées au cours du transport ou du stockage, permettant ainsi aux cellules souches administrées datteindre de façon stable un tissu cible et de présenter lactivité associée dune manière plus efficace, augmentant ainsi remarquablement les effets de la thérapie cellulaire à laide de cellules souches.본 발명은 줄기세포의 파쇄 및 응집 방지 방법에 관한 것이다. 본 발명은 또한, 줄기세포가 아스피린 함유 용액에 부유되어 있는 것을 특징으로 하는 혈관 투여용 줄기세포 조성물에 관한 것이다. 본 발명은 또한, 줄기세포가 아스피린 함유 용액에 부유되어 있는 것을 특징으로 하는 줄기세포의 파쇄 또는 응집 방지용 조성물에 관한 것이다. 본 발명에 따르면, 이송이나 보관 중 세포의 파쇄 및 응집을 방지할 수 있어, 투여된 줄기세포가 안정적으로 표적 조직에 도달하여 활성을 나타내는 효능을 보다 효율적으로 높일 수 있으므로 줄
